Treatment of refractory category III nonbacterial chronic prostatitis/chronic pelvic pain syndrome with intraprostatic injection of onabotulinumtoxinA: A prospective controlled study

Theodor Bilharz Research Institute

Bibliographic Information

Authors: Hamoda T.A.-A.A.-M.; Mosli H.A.; Farsi H.; Alsayyad A.; Tayib A.; Sait M.; Abdelsalam A.

Journal: Canadian Journal of Urology

Publisher: Canadian Journal of Urology

Publication Date: 2018

Volume / Issue: Volume 25 / Issue 2

Pages: 9273–9280

ISSN: 11959479

Scopus: View on Scopus

PubMed: 29680006

Document Type: Article


Authors and Affiliations

Hamoda T.A.-A.A.-M., Department of Urology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia, Department of Urology, Minia University, El Minia, Egypt; Mosli H.A., Department of Urology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; Farsi H., Department of Urology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; Alsayyad A., Department of Urology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; Tayib A., Department of Urology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; Sait M., Department of Urology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; Abdelsalam A., Department of Urology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia, Department of Urology, Theodor Bilharz Research Institute, Cairo, Egypt


Abstract

Introduction: To evaluate the efficacy and safety of intraprostatic injections of onabotulinumtoxinA (onaBoNT-A) to treat refractory chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Materials and methods: Prospective two-group controlled study. Treatment group included adult men with refractory category-III nonbacterial CP/CPPS who underwent transurethral intraprostatic injections of onaBoNT-A (200 U). Control group included comparable patients who underwent cystoscopy only. Primary outcome was the proportion of 6-point responders (= 6 points reduction of total score of National Institutes of Health-Chronic Prostatitis Symptom Index [NIH-CPSI]), at 3 months. Secondary outcomes included proportions of quality of life (QoL) responders (≤ 2 points in QoL domain), and global response assessment (GRA) responders (patients reporting moderately improved, or markedly improved), at 3 months. Other outcomes comprised changes from baseline NIH-CPSI scores, visual analog scale (VAS) sub-score of pain domain, PSA, prostate volume, post-void residual urine, and maximum flow rate. Significance was set at p < 0.05. Results: Treatment group included 43 patients with mean age (SD) of 38.8 (7.3) years and mean duration of symptoms of 7.0 (2.9) years. At 3 months, the proportions of responders (NIH-CPSI 6-point, QoL, and GRA) were 72.1%, 69.8%, and 72.1%; which gradually declined to 37.2%, 25.7% and 27.9%, respectively, at 12 months. The baseline NIH-CPSI total score demonstrated -68.2% reduction at 3 months (-20.1 points; p < 0.0001); which gradually waned to -19% reduction (-5.6 points; p < 0.0001) at 12 months. Baseline VAS showed -79%, and -27.4% reductions at 3 and 12 months, respectively (p < 0.0001, each). None of control men has been 6-point, QoL nor GRA responder and none has demonstrated significant NIH-CPSI scores changes from baseline (p > 0.05, each). Compared to control, mean NIH-CPSI total scores of treated men at 1 and 3 months were significantly different (p < 0.001, each). Conclusion: OnaBoNT-A intraprostatic injections appeared to be effective and safe to ameliorate symptoms of refractory nonbacterial CP/CPPS; with pain most improved. The improvements gradually dwindled at 9-12 months. © The Canadian Journal of Urology™.


Keywords

Chronic prostatitis symptom index; Chronic prostatitis/chronic pelvic pain syndrome; OnabotulinumtoxinA; Adult; Botulinum Toxins, Type A; Chronic Disease; Chronic Pain; Cystoscopy; Humans; Injections, Intralesional; Male; Middle Aged; Pain Measurement; Pelvic Pain; Prospective Studies; Prostatitis; Quality of Life; Reference Values; Risk Assessment; Syndrome; Treatment Outcome; botulinum toxin A; complication; controlled clinical trial; controlled study; human; intralesional drug administration; microbiology; procedures; prospective study; reference value


Citation Information

Scopus Citations: 21


For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.

The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.

English Website: https://www.tbri.sci.eg/en/

Arabic Website: https://www.tbri.sci.eg/ar/

Prepared and Uploaded by:

Abdalla F. Abdalla

Electronic Portal Unit

Electronic Portal Unit

Popular Posts

A cost-performance index for nano-optical biosensor evaluation: Systematic evaluation of europium–salicylate luminescent platforms for GPC3-targeted early HCC diagnosis

Interpretation of liver stiffness measurement in patients with mixed liver disease etiologies

Holothuria arenicola Extract-Loaded Polycaprolactone Nanocapsules Attenuate Bile Duct Ligation-Induced Acute Liver Injury

Variable clinical presentations of pulmonary hydatid cysts: a four-case series from a single center in United Arab Emirates, non-endemic region

Mytilus edulis-mediated green synthesis of selenium nanoparticles with antimicrobial and molluscicidal applications

Corrigendum to ‘Eco-friendly approach for the removal and simultaneous detection of cyanide toxins from drinking and wastewater sources’ [Environ. Pollut. 385 (2025) 127094]

Multifunctional polycaprolactone-based composite fibers with icariin and glutathione for effective repair of critical-sized bone defects